Jordana Joy, Associate Editor

The bill, which passed on May 1, allows for West Virginian ODs to provide certain in-office procedures.

The 3200 square-foot unit offers diagnostics, cataract surgery, YAG laser capsulotomy, and post op care.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

The drug was previously approved for high blood pressure in 1955.

Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO, provided their insights during CIME 2025 on May 4.

Catch up on the top stories in optometry during the week of May 5-May 9.

The first-in-class endothelin antagonist intravitreal implant aided in increasing ocular blood flow and improved both visual function and anatomic structure, according to the company.

The Early Detection of Vision Impairments for Children Act (EDVI), or HR 2527, would allow the federal government to award grants and cooperative agreements to eligible states and communities for children's vision care initiatives.

The LuxLife full range of vision IOL is available in a range of cylinders spanning from +0.75D to +6.00D.

The recombinant human VEGFR antibody human complement receptor 1 (CR1) fusion protein will be intravitreally administered in up to 150 patients.

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.

After treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the following 12 months after treatment was ceased.

Reed will be honored with the Doctor of Ocular Science honorary degree in part of the college’s 2025 commencement.

The law is the product of a 2-year collaborative effort by the North Dakota Optometric Association and the North Dakota State Board of Optometry.

What to know about legislative moves that have been made through May this year.

Catch up on the top stories in optometry during the week of April 28-May 2.

The CATHAY trial evaluated 186 myopic children, 6 to 13 years old at initiation, across 5 hospitals.

Rhue and Canto-Sims tackle the problem of many optometry practices losing significant revenue due to ineffective follow-up systems.

The strikes follow the University of California’s hiring freeze implemented on March 19.

This expansion marks the first FDA clearance for an amblyopia treatment for this age range in more than 2 decades.

Of participants surveyed, 36% reported a fear of cataract surgery, with more than half of those specifically feared it would lead to vision loss.

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long term safety and efficacy of MINIject in patients with up to 5 years of follow up.

Rhue and Canto-Sims talk about the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.

Maxitrol has been the leading corticosteroid/antibiotic combination drop for the treatment of ocular inflammation and bacterial infections for more than 50 years.

The optimal triple-carotenoid supports daily eye health with lutein, zeaxanthin, and meso-zeaxanthin, according to the company.

Rhue and Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.

Catch up on the top stories in optometry during the week of April 21-April 25.

Matt Jones, OD; Matt Burns; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.

Participants received either Systane Hydration UD (Alcon, Fort Worth, TX) or saline eye drops (NeilMed, Santa Rosa, CA) 4 times a day for 4 weeks each.

Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.